Severe Alopecia Areata
Conditions
Keywords
Ritlecitinib, Alopecia Areata
Brief summary
This study is a secondary analysis of the Adelphi Real World Alopecia Areata II United States Disease Specific Programmes database. This database contains data from a cross-sectional study capturing linked physician and patient survey data for dermatologists who treat alopecia areata and patients diagnosed with alopecia areata in the United States. The retrospective analysis of these data will evaluate experiences of patients and dermatologists receiving/prescribing ritlecitinib for severe alopecia areata in the United States. Specifically, the study will describe characteristics of patients who received ritlecitinib for severe alopecia areata, including demographics, clinical characteristics at the time of starting ritlecitinib, and their alopecia areata-related treatment history. The study will also report dermatologist satisfaction with treatment and change in the patient's alopecia areata severity and disease activity from the start of ritlecitinib to different time points on treatment.
Interventions
DRUGRitlecitinib
As provided in real world practice
Sponsors
Pfizer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Aged 18 years or older with severe alopecia areata
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| % of patients for whom their clinician was "satisfied" with current control of alopecia areata | 11/15/2023 to 06/10/2024 |
| % of patients with clinician-assessed mild, moderate, or severe disease | 11/15/2023 to 06/10/2024 |
| % of patients with clinician assessed progressive, stable, or improving disease | 11/15/2023 to 06/10/2024 |
Countries
United States
Contacts
STUDY_DIRECTORPfizer CT.gov Call Center
Pfizer
Outcome results
None listed